AAV Gene Therapy Market, By Vector Serotype (AAV9, AAV2, AAV5, AAV8, AAV1, and Engineered/Synthetic AAV Variants), By Therapeutic Area (Neurological Disorders, Ophthalmic Disorders, Rare Genetic Disorders, Hematological Disorders, Muscular Disorders, Metabolic Disorders, Cardiovascular Disorders, Oncology, and Others), By Target Tissue (Central Nervous System, Eye/Retina, Liver, Muscle, Lung, Heart, and Blood/Bone Marrow By Route of Administration: Intravenous, Intrathecal, Intracerebral, Subretinal, Intravitreal, Intramuscular, and Intracardiac), By Indication Type (Monogenic Disorders and Polygenic Disorders), By Gene Payload Type (Gene Replacement, Gene Silencing, and Gene Augmentation), By Development Stage (Preclinical, Phase I, Phase II, and Phase III), By Manufacturing Type (In-house Manufacturing and Contract Manufacturing (CDMO/CMO)), By End User (Biopharmaceutical Companies, Research Institutes and Academic Centers, Hospitals and Specialty Clinics, and Others (CROs)), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Growth Trends and Forecasts (2026-2033)